Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
Sponsor: Liaoning Cancer Hospital & Institute
A PHASE4 clinical study on Gastric / Gastroesophageal Junction Adenocarcinoma, this trial is actively recruiting participants. The trial is conducted by Liaoning Cancer Hospital & Institute and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recordedEligibility Summary
No eligibility information available.
Contact Information
- Liaoning Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.